Gapping up
In reaction to strong earnings/guidance: UEC +3.6%, LFVN +1%
M&A news: BUD +1.5% (to divest SABMiller's Central and Eastern European Business to Asahi (ASBRF) for EUR7.3 bln)
Select EU financial related names showing strength: DB +2.7%, BBVA +1.9%, SAN +1.8%, CS +1.3%, BCS +1.1%, HSBC +1%
Select oil/gas related names showing strength: KEY +3.7%, WTI +2.7%, CEO +2.6%, NE +2.5%, CHK +2%, ESV +2%,RIG +1.7%, WLL +0.7%, XOM +0.7%
Other news:
In reaction to strong earnings/guidance: UEC +3.6%, LFVN +1%
M&A news: BUD +1.5% (to divest SABMiller's Central and Eastern European Business to Asahi (ASBRF) for EUR7.3 bln)
Select EU financial related names showing strength: DB +2.7%, BBVA +1.9%, SAN +1.8%, CS +1.3%, BCS +1.1%, HSBC +1%
Select oil/gas related names showing strength: KEY +3.7%, WTI +2.7%, CEO +2.6%, NE +2.5%, CHK +2%, ESV +2%,RIG +1.7%, WLL +0.7%, XOM +0.7%
Other news:
- IDXG +32.2% (launches a multi-site study to provide further evidence of the Clinical Utility of the ThyGenX/ThyramiR tests)
- AKAO +13% (following ~150% move higher; commences 5.75 mln common stock offering)
- APRI +11.7% (following ~50% move higher)
- SCYX +7.6% (has identified an IV formulation and dose regimen that, pending discussions with the FDA, co plans to test in the upcoming clinical trials of SCY-078)
- ATNM +7.2% (submits an application w/ the EMA seeking Orphan Designation for Actimab-A)
- AUPH +6.2% (receives the final End of Phase II meeting minutes from the FDA)
- RVNC +5.3% (announces positive interim results from its U.S. Phase 2 open-label, dose-escalating clinical study of DaxibotulinumtoxinA Injectable (RT002) to treat moderate-to-severe isolated cervical dystonia in adults)
- LIFE +2.7% (clinical results from exploratory trials assessing the safety and potential activity of Resolaris)
- LVS +2.1% (Japan upper house approves gambling bill)
- MGM +1.9% (Japan upper house approves gambling bill)
- NVCR +1.7% (will present data from its phase 2 pilot PANOVA clinical trial at its R&D day on Dec. 12 suggesting that TTFields plus first-line chemotherapies nab-paclitaxel and gemcitabine may be tolerable and safe in patients with advanced pancreatic cancer)
- BA +1.5% (increases quarterly dividend to $1.42/share from $1.09/share; replaces existing share repurchase program with a new $14 billion authorization )
Analyst comments:
- UN +1.3% (upgraded to Buy from Hold at Jefferies )
- O +0.8% (upgraded to Overweight from Equal-Weight at Morgan Stanley)
- FDX +0.6% (initiated with a Overweight at JP Morgan)